istock-896469402-stuart-ritchie

Stuart Ritchie / iStockphoto.com

30 August 2018Americas

FDA warns 21 websites over misbranded opioid drugs

The US Food and Drug Administration (FDA) has warned 21 websites over the illegal marketing of misbranded versions of opioid medications.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

FDA and DEA warn over sale of misbranded opioid drugs

1 October 2019 The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines.

Emergent BioSolutions to buy Adapt Pharma for $735m

30 August 2018 Life sciences company Emergent BioSolutions announced plans to acquire Adapt Pharma earlier this week, in what the company said was an effort to combat the public health threat from opioid overdose.

More on this story

FDA and DEA warn over sale of misbranded opioid drugs

1 October 2019 The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines.

Emergent BioSolutions to buy Adapt Pharma for $735m

30 August 2018 Life sciences company Emergent BioSolutions announced plans to acquire Adapt Pharma earlier this week, in what the company said was an effort to combat the public health threat from opioid overdose.

More on this story

FDA and DEA warn over sale of misbranded opioid drugs

1 October 2019 The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines.

Emergent BioSolutions to buy Adapt Pharma for $735m

30 August 2018 Life sciences company Emergent BioSolutions announced plans to acquire Adapt Pharma earlier this week, in what the company said was an effort to combat the public health threat from opioid overdose.

More features

WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’

Powell Gilbert launches Düsseldorf office with leading patent litigator

Startups toolkit: Why investors want more than patents

J&J fends off generic schizophrenia drug bids

Kilpatrick adds ‘seasoned litigator’ as trademark partner

WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond

Startup challenges rival over brain monitoring tech at ITC